Literature DB >> 6737669

Medical resources after nuclear war. Availability v need.

H L Abrams.   

Abstract

In defining capacity to "survive" a massive nuclear exchange, it is important to assess the medical resources that will be available in the post-nuclear war world. Approximately 80% of these resources--hospital beds and personnel, blood, drugs, and medical supplies--will have been destroyed, since they are located in or near the densely populated areas that constitute primary targets of attack. Casualty estimates published by federal agencies, together with data from the Hiroshima-Nagasaki experience, suggest the numbers and types of injuries that will afflict the US population. With a probable 48,000 surviving physicians to treat 32 million casualties, there will be one physician for every 663 patients. Of the trauma and burn victims, approximately 55% will require hospitalization; this will mean 64 patients for each available hospital bed. Data from recent wars have been utilized to determine the trauma-related blood requirements in the post-nuclear war world. Of the 64 million units of whole blood needed, only 14,000 will be available. Other medical resources will be in equally short supply. This disparity between need and availability indicates the difficulty of developing a meaningful medical response for the surviving injured.

Entities:  

Keywords:  War and Human Rights Abuses

Mesh:

Substances:

Year:  1984        PMID: 6737669

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  2 in total

1.  Mice and the A-Bomb: Irradiation Systems for Realistic Exposure Scenarios.

Authors:  Guy Garty; Yanping Xu; Carl Elliston; Stephen A Marino; Gerhard Randers-Pehrson; David J Brenner
Journal:  Radiat Res       Date:  2017-02-17       Impact factor: 2.841

2.  Nuclear war between Israel and Iran: lethality beyond the pale.

Authors:  Cham E Dallas; William C Bell; David J Stewart; Antonio Caruso; Frederick M Burkle
Journal:  Confl Health       Date:  2013-05-10       Impact factor: 2.723

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.